Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) granted inducement equity awards under its 2025 Inducement Plan on April 14, 2026. The Compensation Committee awarded options for 68,500 ADS and 57,765 RSUs to 15 employees, with options priced at $1.47 and ten-year terms.
Options vest over four years (25% after one year, then monthly over three years); RSUs vest in four equal annual installments. Awards are conditioned on continued service and were granted as inducements under Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
On the day this news was published, AUTL gained 3.12%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AUTL was down 1.25% with light volume while peers showed mixed moves: declines in names like CGEM (-3.2%) and AURA (-2.35%), but a gain in YMAB (+0.23%). No momentum scanner flags or common headlines suggest a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | Conference participation | Neutral | -2.2% | Investor conference participation and webcasts announced for April 2026. |
| Mar 27 | Earnings and outlook | Positive | -6.2% | Reported 2025 revenue and AUCATZYL guidance with outlook to positive gross margin. |
| Mar 16 | Earnings date set | Neutral | +0.0% | Announced timing and access details for Q4 and full-year 2025 results call. |
| Feb 24 | Conference participation | Positive | +5.2% | Outlined March 2026 investor events featuring CEO presentations and meetings. |
| Feb 04 | Inducement grants | Neutral | +0.0% | Announced prior inducement stock option awards under Nasdaq Listing Rule 5635(c)(4). |
Recent news often saw negative or flat price reactions even to seemingly constructive updates, while routine administrative items like inducement grants have drawn neutral responses.
Over the last few months Autolus has moved from conference visibility and earnings updates to governance and equity-administration items. Earnings on March 27, 2026 highlighted growing AUCATZYL revenue and 2026 guidance but the stock fell 6.2%. Multiple conference participation releases had mixed impact, from 0% to +5.2%. A prior inducement grant announcement on February 4, 2026 saw a 0% move, suggesting these employee-equity issuances have not been major trading catalysts.
Regulatory & Risk Context
An effective S-3 shelf filed on April 10, 2026 allows Autolus to offer up to $150,000,000 of securities over time, with proceeds earmarked for clinical development, manufacturing, commercialization and general corporate purposes. No usage has been recorded yet, so any future takedowns would come via separate prospectus supplements.
Market Pulse Summary
This announcement details routine inducement equity awards—68,500 stock options and 57,765 RSUs—to 15 new employees under Nasdaq Listing Rule 5635(c)(4), with a $1.47 exercise price and four-year vesting. In context, Autolus recently filed a $150,000,000 Form S-3 shelf and reported 2025 revenue growth and guidance. Investors may monitor how ongoing hiring, equity incentives and any future shelf usage interact with the company’s cash runway and commercial ramp.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
exercise price financial
vesting financial
AI-generated analysis. Not financial advice.
LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 68,500 American Depositary Shares and 57,765 restricted stock units (RSUs), each representing an equal number of ordinary shares, to 15 employees pursuant to the Company’s 2025 Inducement Plan. The stock options and RSUs were granted as an inducement material to the individual becoming an employee of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option awards and RSUs have a grant date of April 14, 2026. The stock option awards have an exercise price of
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
Executive Director, Investor Relations & External Communications
+1 617-967-0207
a.cray@autolus.com
